Skip to main content
Premium Trial:

Request an Annual Quote

C. Evan Ballantyne, Joseph Whitters, Craig Taylor, Genghis Lloyd-Harris, Mason Morfit

Premium
Clinical Data this week announced that it had appointed C. Evan Ballantyne as senior vice president and CFO. Ballantyne replaces Israel Stein, the company's interim chief financial officer and former president and CEO.
 
Ballantyne served most recently as senior vice president and CFO of ZymeQuest, a Beverly, Mass.-based medical device company. Prior to that position, he was CFO of Wayland, Mass.-based Knowledge Impact.
 
Ballantyne has also served as vice president and COO for ACNielsen Corporation, and later worked as the company’s CFO for two years. He also worked for Dun & Bradstreet as an auditor.
 
Ballantyne earned a BA from the University of Western Ontario, followed by a post-graduate degree in business administration from the University of Windsor.
 

 
Joseph Whitters joined Solexa’s board of directors, the company said yesterday. He will serve as chairman of the compensation committee.
 
According to documents filed with the Securities and Exchange Commission yesterday, Whitters will also provide advisory and other consulting services to Solexa as an independent contractor. He will receive a grant of up to 7,500 shares of the company’s unvested common stock. The shares will vest as they are earned through the provision of consulting services, the filing said.
 
Whitters was chief financial officer at First Health Group and was executive vice president at the time of its sale to Coventry Health Plans. Prior to First Health, he was a controller for United HealthCare and a manager of accounting and taxation at Overland Express.
 
A former advisory committee participant for NASDAQ, Whitters currently serves on the boards for Mentor, Luminent Mortgage Capital, and Omnicell.
 
Whitters received his bachelor's degree in accounting from Luther College.
 
Solexa also said Craig Taylor and Genghis Lloyd-Harris resigned from the board on July 28. According to the SEC filing, the board appointed Stephen Allen and Douglas Fambrough to the audit committee and appointed Mason Morfit as chairman of the nominating and corporate governance committee and chairman of the audit committee.

Filed under

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.